AstraZeneca Launches its Ninth GMD Centre in Bengaluru
AstraZeneca, a global science-led biopharmaceutical company launched its new Global Medicines Development (GMD) centre in Bengaluru. Being one of the nine GMD centers around the world, the Bengaluru unit transforms molecules into medicines and monitors their use and builds capabilities in regulatory science.
Elisabeth Bjork, VP, Global Medicines Development Unit Head for Cardiovascular Metabolic Renal Diseases, AstraZeneca, says, “AstraZeneca has a long-standing commitment in India over 40 years. The GMD expansion is part of AstraZeneca’s continued commitment to enhance scientific innovation in the country and I am delighted to open our newest GMD site and to welcome our new colleagues to the AstraZeneca team.”
The GMD unit in Bengaluru focuses on supporting AstraZeneca’s medicines, which helps treatments in therapy areas including oncology, respiratory and cardiovascular and metabolic diseases. Several scientific experts in the fields of regulatory science, clinical and patient safety have been recruited.
Veena Rajan, GMD Site Lead Bengaluru, AstraZeneca India, says, “We plan to recruit more physicians, scientists and regulatory experts to support the GMD Bengaluru, and continue to deliver value for our global mature brands in oncology, respiratory, cardiovascular and metabolic diseases.”
Founded in 1999 and headquartered at London, AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. It operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. At present, AstraZeneca is present in India as two legal entities namely, AZPIL (AstraZeneca Pharma India Limited) and AZPIL (AstraZeneca India Private Limited).
Read more news:
